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University of Tokyo, Tokyo, JapanIntroduction: Although polycystic liver disease (PCLD) is one of the extrarenal complications in patients
with autosomal dominant polycystic kidney disease (ADPKD), longitudinal changes and the association
with total liver volume (TLV) have not been clearly elucidated yet.
Methods: Patients with ADPKD were chosen who underwent computed tomography or magnetic reso-
nance imaging twice or more during August 2003 through December 2015. TLV, each cyst volume, and the
proportion of parenchyma were measured. The natural history of liver cysts and the association between
TLV and liver cysts were evaluated. To compare with liver cysts in ADPKD patients with PCLD, simple liver
cysts in patients without ADPKD were also evaluated.
Results: TLV at baseline and its growth rate in all the patients with ADPKD, whose serum creatinine,
estimated glomerular ﬁltration rate, and total kidney volume were 1.45 mg/dl (0.76–2.32 mg/dl), 38.5 ml/
min per 1.73 m2 (18.7–57.9 ml/min per 1.73 m2), and 1394 ml (773–2861 ml), were 1431 ml (1062–1749 ml)
and 0.95%/yr (3.16 to 4.94%/yr), respectively, in the observation period (median, 1063 days). Neither
TLV nor its growth rate was signiﬁcantly different between ADPKD patients with PCLD and those without
PCLD. The growth rate of 79 liver cysts was 39.5%/yr (17.5–80.8%/yr) in PCLD patients with ADPKD. It was
signiﬁcantly larger than that of 60 simple liver cysts in the non-ADPKD group, 11.0%/yr (2.2 to 33.1%/yr).
Moreover, the proportion of parenchyma reduced, whereas that of total cyst volume increased signiﬁ-
cantly (P ¼ 0.001).
Discussion: The reduction of parenchyma was accompanied by the growth of liver cysts during time
course in PCLD patients with ADPKD.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B efore the emergence of tolvaptan, therapeuticstrategy consisted of supportive treatment such as
blood pressure control in autosomal dominant polycy-
stic kidney disease (ADPKD), and direct treatment
against renal cyst enlargement was unavailable. The
main cause of ADPKD included renal failure, heart
failure, and cerebrovascular disease such as subarach-
noid hemorrhage decades ago.1spondence: Kenjiro Honda, Department of Nephrology and
rinology, University Hospital, The University of Tokyo, 7-3-1
, Bunkyo, Tokyo 113-8655, Japan. E-mail: khonda-tky@
ac.jp
ved 9 August 2016; revised 22 September 2016; accepted 27
mber 2016; published online 6 October 2016The Tolvaptan Efﬁcacy and Safety in Management
of Autosomal Dominant Polycystic Kidney Disease and
its Outcomes (TEMPO) 3:4 trial2 showed that tolvaptan
slowed both the increase in total kidney volume (TKV)
and the decline of renal function in ADPKD. This novel
treatment will possibly change the clinical course in
ADPKD. It is expected that tolvaptan will delay the age
of dialysis initiation in patients with ADPKD.3,4 Because
dialysis management has been improved in recent
years,5 patients can undergo better medical treatment
even after dialysis initiation. Thus, patients with
ADPKD would receive beneﬁt from management of
chronic kidney disease in predialysis and dialysis pe-
riods. Furthermore, screening of intracranial aneurysm
is recommended to improve their prognosis in Japan.4Kidney International Reports (2017) 2, 60–65
R Matsuura et al.: Liver Cysts in Patients With ADPKD and PCLD CLINICAL RESEARCHAs a result of the medical advance, the life expectancy
of patients with ADPKD would elongate, and nephrol-
ogists would have more chance to see patients with
ADPKD with or without renal replacement therapy.5
Polycystic liver disease (PCLD) is the major extra-
renal complication in patients with ADPKD.6,7 Some
ADPKD patients with PCLD present various clinical
symptoms such as abdominal fullness, pain, and early
satiety that lower their quality of life. They also have
some complications such as leg edema and portal hy-
pertension. Moreover, a certain number of patients
experience annoying events such as cystic infection,
hemorrhage, and rupture.8,9 Especially, infection
including cystic infection was the third cause of death
among patients with ADPKD in Japan. Because better
management of chronic kidney disease and brain
aneurysm is provided, liver involvement will be more
frequent in ADPKD henceforth.
Symptoms and complications related to ADPKD
have become more frequent in patients with ADPKD
at older age.10 This clinical course suggests that cyst
growth may be associated with cyst infection. From this
viewpoint, it is clinically useful to clarify the time course
of liver and renal cysts. The association between cyst
volume and TKVwas reported, whereas liver cysts were
previously evaluated in a few studies.11–14 Furthermore,
the former reports of PCLD in patientswithADPKDwere
cross-sectional studies,11–14 and longitudinal changes
and the association with total liver volume (TLV) have
not been clearly elucidated yet.
In this study, we show the characteristics of PCLD in
patients with ADPKD, comparing them with non-PCLD
patients with and without ADPKD.METHODS
Patients and Deﬁnitions
Adult patients (>18 years old) clinically diagnosed
with ADPKD were enrolled who underwent computed
tomography or magnetic resonance imaging twice or
more during August 2003 through December 2015 at the
University of Tokyo Hospital. The diagnosis of ADPKD
was based on 5 or more cysts in each kidney detected
by images, family history, and comorbidity after other
cystic kidney diseases could be excluded.4 These patients
were divided into 2 groups: patients with PCLD (PCLD
group) and thosewithout PCLD (non-PCLDgroup). PCLD
was deﬁned as having 15 or more liver cysts at computed
tomography or magnetic resonance imaging.15
Likewise, 34 patients without ADPKD with a few
liver cysts were selected as control. All the patients
without ADPKD were diagnosed with simple liver cysts.
Parameters checked at baseline were as follows: age,
sex, body height, body weight, body mass index, bodyKidney International Reports (2017) 2, 60–65surface are, blood pressure, aspartate transaminase,
alanine transaminase, alkaline phosphatase, creatinine,
sodium, potassium, white blood cell, hemoglobin, and
platelets.
Measurements of Total Liver Volume, Liver Cyst
Volume, and Total Kidney Volume
Both TLV and liver cyst volume were measured using
the image processing software ImageJ (National In-
stitutes of Health, Bethesda, MD).16 TLV and each liver
cyst volume were calculated as the sum of cross-
sectional areas times slice thickness. Liver cysts with
the diameter of more than 2 cm were selected at the last
computed tomography or magnetic resonance imaging
because it was difﬁcult to evaluate the accurate change
in the size of small cysts. The parenchymal volume was
calculated as the sum of cross-sectional areas after
adjusting each liver slice (3–6 mm). Height-adjusted
TLV was calculated as the ratio of TLV to body
height.14 In case of multiple scans, we compared the
oldest scan with the latest scan.
TKV was estimated from maximum length (L), width
(W), and height (H), using the formula for an ellipsoid:
p/6LWD.
All the measurements were performed by 2 inde-
pendent well-trained nephrologists.
Analysis
Data were shown as median (interquartile range). Sta-
tistical analyses were performed by the Mann-Whitney
test when comparing between groups or the Wilcoxon
signed-rank test when comparing between baseline and
time-proceeding data in the same group because all
data were not parametric. The cubic approximation of
cyst volume was applied using cyst diameter with
analysis of variance. Statistical analyses were per-
formed by JMP Pro 11 for Windows (SAS Institute
Japan, Tokyo). The signiﬁcant difference was deﬁned
as P value < 0.05.
RESULTS
Total Liver Volume in the PCLD and Non-PCLD
Groups
Of 36 patients with ADPKD in our hospital, 23 patients
were eligible for this study. Among them, 13 patients
were included in the PCLD group. The observation
interval was 1063 days (203–2373 days). Baseline
characteristics are shown in Table 1. No parameters
were signiﬁcantly different between the PCLD group
and the non-PCLD group with ADPKD at baseline. No
patients with ADPKD had elevated liver enzyme and
had been treated with somatostatin analog or immu-
nosuppressive agents such as mammalian target of
rapamycin inhibitors before.61
Table 1. Characteristics of patients with ADPKD
All (n [ 23) PCLD (n [ 13) Non-PCLD (n [ 10) P value
Age 54 (46–67) 65 (46–67) 50 (43–63) 0.47
Male/female 12/11 6/7 6/4 0.51
Body height (m) 1.66 (1.56–1.74) 1.64 (1.55–1.73) 1.66 (1.55–1.75) 0.83
Body weight (kg) 68.2 (49.3–72.0) 55.0 (46.4–70.2) 71.0 (49.8–79.8) 0.15
BMI (kg/m2) 22.6 (19.2–25.2) 21.0 (18.5–23.7) 23.9 (21.1–28.0) 0.10
BSA (m2) 1.73 (1.39–1.84) 1.58 (1.37–1.78) 1.79 (1.46–1.87) 0.25
Hypertension 21 (91%) 12 (92%) 9 (90%) 1.00
sBP (mm Hg) 130 (120–143) 130 (121–140) 132 (120–150) 0.72
dBP (mm Hg) 80 (76–87) 81 (71–88) 80 (78–87) 1.00
AST (U/l) 19 (15–23) 21 (16–23) 19 (15–24) 0.69
ALT (U/l) 15 (12–20) 17 (13–21) 14 (11–19) 0.40
T-Bil (mg/dl) 0.65 (0.50–0.95) 0.65 (0.43–0.95) 0.65 (0.60–1.02) 0.61
Alb (g/dl) 4.1 (3.9–4.2) 4.0 (3.7–4.2) 4.1 (4.0–4.3) 0.44
Cr (mg/dl) 1.45 (0.76–2.32) 1.45 (0.76–2.21) 1.49 (0.84–3.70) 0.76
eGFR (ml/min per 1.73 m2) 38.5 (18.7–57.9) 38.5 (18.5–57.8) 39.9 (18.4–60.8) 0.93
Na (mEq/l) 140 (139–142) 141 (139–142) 140 (135–142) 0.48
K (mEq/l) 4.5 (4.0–4.7) 4.3 (3.8–4.6) 4.7 (4.2–4.9) 0.23
WBC (per ml) 5000 (4100–7100) 5000 (4300–6200) 5700 (4000–8500) 0.74
Hb (g/dl) 12.7 (11.3–14.1) 12.7 (11.2–14.4) 12.7 (11.2–14.0) 0.85
Plt (104/ml) 20.7 (16.7–24.3) 18.5 (16.9–25.4) 21.2 (16.6–24.7) 0.95
TKV (ml) 1394 (773–2861) 991 (568–2134) 2127 (848–5093) 0.23
htTKV (ml/m) 776 (471–1626) 580 (359–1354) 1234 (526–3179) 0.16
TLV (ml) 1431 (1062–1749) 1538 (1171–1978) 1227 (969–1566) 0.18
htTLV (ml/m) 847 (639–1013) 879 (676–1241) 738 (621–895) 0.18
ADPKD, autosomal dominant polycystic kidney disease; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; BSA, body surface area; Cr, creatinine; dBP,
diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; Hb, hemoglobin; htTKV, height-adjusted total kidney volume; htTLV, height-adjusted total liver volume; PCLD,
polycystic liver disease; Plt, platelet; sBP, systolic blood pressure; T-Bil, total bilirubin; TKV, total kidney volume; TLV, total liver volume; WBC, white blood cell.
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Figure 1. TLV change in patients with ADPKD. The vertical axis
represents the change of TLV compared with baseline (%), whereas
the horizontal axis represents time (days). ADPKD, autosomal
dominant polycystic kidney disease; PCLD, polycystic liver disease;
TLV, total liver volume.
CLINICAL RESEARCH R Matsuura et al.: Liver Cysts in Patients With ADPKD and PCLDTLV and its growth rate in all the patients with
ADPKD were 1431 ml (1062–1749 ml) and –0.95%/yr
(–3.16 to 4.94%/yr), respectively. TLV and its growth
rate were 1536 ml (1171–1978 ml) and –0.95%/yr (–2.78
to 19.6%/yr) in the PCLD group, whereas they
were 1227 ml (969–1566 ml) and –0.38%/yr (–8.63 to
3.47%/yr), respectively, in the non-PCLD group.
Neither TLV nor its growth rate was signiﬁcantly
different between the groups (Figure 1). In addition,
there was no association between TLV and TKV.
The Characteristics of Liver Cysts in PCLD
Patients With ADPKD
The number of calculated cysts in PCLD patients with
ADPKD was 79, and the median volume was 3.05 ml
(1.69–5.84 ml). If the maximum diameter of cyst was
deﬁned as X (mm), the volume of cyst Y (ml) was
approximated by the following formula: Y ¼ 0.0007X3
– 0.0318X2 þ 0.5137X (r2 ¼ 0.92, P < 0.001) (Figure 2).
All liver cysts in PCLD patients with ADPKD
enlarged in the observation period, and the increasing
rate of liver cysts in the PCLD group was 39.5%/yr
(17.5–80.8%/yr). This was signiﬁcantly larger than
11.0%/yr (–2.2 to 33.1%/yr) in the control group
without ADPKD (n ¼ 60) (Figure 3). The growth rate of
liver cysts did not correlate with that of TLV and TKV
(data not shown).62The Proportion of Parenchyma and Liver Cysts
in PCLD Patients With ADPKD
The proportion of parenchyma and cysts were
evaluated because TLV was unchanged despite the
enlargement of each cyst volume. The proportion of
parenchyma decreased signiﬁcantly from 71.718.0%Kidney International Reports (2017) 2, 60–65
Figure 2. Association between liver cyst volume and the diameter of
cyst in PCLD patients with ADPKD. ADPKD, autosomal dominant
polycystic kidney disease; PCLD, polycystic liver disease.
R Matsuura et al.: Liver Cysts in Patients With ADPKD and PCLD CLINICAL RESEARCHat baseline to 65.016.8% at proceeding time. On the
other hand, the proportion of cysts increased signiﬁ-
cantly from 28.318.0% at baseline to 35.016.8% at
proceeding time (P ¼ 0.001, Figure 4a and b).
DISCUSSION
PCLD is the major extrarenal complication in patients
with ADPKD. This study showed the clinical course of
liver cysts in patients with ADPKD, and clariﬁed some
characteristics.
First, liver cysts in patients with ADPKD were
increasing and never shrinking. As shown in
Figures 4 and 5, all liver cysts in patients with ADPKD
enlarged with various growth rates, whereas not all
simple liver cysts enlarged. This characteristic was
supported by the result in a previous report that liver
cyst volume was associated with age.6day
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Figure 3. (a) Clinical course of cyst growth in PCLD patients with ADPKD
volume to baseline (day 0) volume. (b) Cyst growth rate in PCLD patien
autosomal dominant polycystic kidney disease; PCLD, polycystic liver dise
Kidney International Reports (2017) 2, 60–65Second, the growth rates of liver cysts did not
correlate with the change of TLV. The result was un-
changed in a case with the lowest growth rate in the
PCLD group. This was inconsistent with some former
studies that concluded that liver cyst volume was
associated with TLV.14,17 However, it is of note that
TLVs in our study were smaller than those in the
previous studies. Unlike the relationship between renal
cysts and TKV, TLV would not reﬂect liver cyst vol-
ume when liver cysts were not enormous. Moreover,
focusing on patients without severely developed liver
cyst volume, it seemed that there were no associations
with cyst volume and TLV. The result was similar to
ours, and it is speculated that cyst volume increased
and parenchymal volume reduced despite unchanged
TLV when TLV was mild to moderate. Indeed, this
speculation could explain the fact that the proportion
of parenchyma volume reduced and the proportion of
cyst volume increased in spite of unchanged TLV, as
shown in Figure 4. When the total liver cyst volume
severely developed, both total cyst volume and TLV
increased, as shown in Figure 5b.
Third, the growth of liver cysts did not correlate
with TKV. The defect of polycystin, encoded by the
causal gene of ADPKD, may contribute to the devel-
opment of liver cysts18,19; however, the factors pro-
moting cyst growth are not clariﬁed. Our result
suggested that the growth factors of liver and kidney
cysts will be different.
Fourth, the growth rate of TLV in some patients was
negative. This was consistent with the previous large
cohort.20 Total liver volume shrinks with aging in healthy
population.21 Shrinkage of parenchyma may have a
stronger impact than cyst growth in some patients.KD
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Figure 4. The proportion of (a) parenchyma and (b) cyst at baseline and time proceeding in PCLD patients with ADPKD. *P ¼ 0.001. ADPKD,
autosomal dominant polycystic kidney disease; PCLD, polycystic liver disease.
CLINICAL RESEARCH R Matsuura et al.: Liver Cysts in Patients With ADPKD and PCLDThere were some limitations of our study. First, the
sample was small. Although previous studies about
PCLD with ADPKD are limited, the fact that the median
of TLV in our report was similar to that in a previous
study22 indicates that selection bias was unlikely in
this study. Second, heterogeneous observation in-
tervals might have affected the change of TLV because
this was a retrospective study. However, liver volume
and its growth rate were consistent with the previous
cohort and these differences had little impact on our
results. A prospective and large clinical study with
the same interval will help develop the perception in
this study. Third, we evaluated only liver cysts
with the maximum diameter of more than 2 cm because
the volume of smaller cysts could not be measured
accurately.Figure 5. The relationship between TLV and cyst volume. (a) When
cyst volume is mild to moderate, parenchymal volume decreases
and TLV does not change, whereas the cyst grows. (b) When cyst
volume is severely developed, cyst volume and TLV correlate. TLV,
total liver volume.
64In conclusion, the change of TLV and liver cysts in
mild-to-moderate PCLD patients with ADPKD was not
paralleled because cyst volume was growing with the
reduction of parenchyma. This is the ﬁrst report that
demonstrated the change of TLV and liver cysts among
PCLD patients with ADPKD.
DISCLOSURE
All the authors declared no competing interests.
REFERENCES
1. Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of
death in autosomal dominant polycystic kidney disease. J Am
Soc Nephrol. 1995;5:2048–2056.
2. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in pa-
tients with autosomal dominant polycystic kidney disease.
N Engl J Med. 2012;367:2407–2418.
3. Gansevoort RT, Arici M, Benzing T, et al. Recommendations
for the use of tolvaptan in autosomal dominant polycystic
kidney disease: a position statement on behalf of the ERA-
EDTA Working Groups on Inherited Kidney Disorders and
European Renal Best Practice. Nephrol Dial Transplant.
2016;31:337–348.
4. Horie S, Mochizuki T, Muto S, et al. Evidence-based clinical
practice guidelines for polycystic kidney disease 2014. Clin
Exp Nephrol. 2016;20:493–509.
5. Spithoven EM, Kramer A, Meijer E, et al. Renal replacement
therapy for autosomal dominant polycystic kidney disease
(ADPKD) in Europe: prevalence and survival—an analysis of
data from the ERA-EDTA Registry. Nephrol Dial Transplant.
2014;29(suppl 4):iv15–iv25.
6. Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance im-
aging evaluation of hepatic cysts in early autosomal-
dominant polycystic kidney disease: the Consortium for
Radiologic Imaging Studies of Polycystic Kidney Disease
cohort. Clin J Am Soc Nephrol. 2006;1:64–69.Kidney International Reports (2017) 2, 60–65
R Matsuura et al.: Liver Cysts in Patients With ADPKD and PCLD CLINICAL RESEARCH7. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-domi-
nant polycystic kidney disease (ADPKD): executive summary
from a Kidney Disease: Improving Global Outcomes (KDIGO)
Controversies Conference. Kidney Int. 2015;88:17–27.
8. Perugorria MJ, Masyuk TV, Marin JJ, et al. Polycystic liver
diseases: advanced insights into the molecular mechanisms.
Nat Rev Gastroenterol Hepatol. 2014;11:750–761.
9. Chauveau D, Fakhouri F, Grunfeld JP. Liver involvement in
autosomal-dominant polycystic kidney disease: therapeutic
dilemma. J Am Soc Nephrol. 2000;11:1767–1775.
10. Lantinga MA, Drenth JP, Gevers TJ. Diagnostic criteria in
renal and hepatic cyst infection. Nephrol Dial Transplant.
2015;30:744–751.
11. Gabow PA, Johnson AM, Kaehny WD, et al. Risk factors for
the development of hepatic cysts in autosomal dominant
polycystic kidney disease. Hepatology. 1990;11:1033–1037.
12. Thomsen HS, Thaysen JH. Frequency of hepatic cysts in
adult polycystic kidney disease. Acta Med Scand. 1988;224:
381–384.
13. Qian Q, Li A, King BF, et al. Clinical proﬁle of autosomal domi-
nant polycystic liver disease. Hepatology. 2003;37:164–171.
14. Kim H, Park HC, Ryu H, et al. Clinical correlates of mass effect
in autosomal dominant polycystic kidney disease. PLoS One.
2015;10:e0144526.
15. Hoevenaren IA, Wester R, Schrier RW, et al. Polycystic liver:
clinical characteristics of patients with isolated polycysticKidney International Reports (2017) 2, 60–65liver disease compared with patients with polycystic liver and
autosomal dominant polycystic kidney disease. Liver Int.
2008;28:264–270.
16. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to
ImageJ: 25 years of image analysis. Nat Methods. 2012;9:
671–675.
17. Hogan MC, Abebe K, Torres VE, et al. Liver involvement
in early autosomal-dominant polycystic kidney disease. Clin
Gastroenterol Hepatol. 2015;13:155–164.e6.
18. Hopp K, Ward CJ, Hommerding CJ, et al. Functional
polycystin-1 dosage governs autosomal dominant polycystic
kidney disease severity. J Clin Invest. 2012;122:4257–4273.
19. Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, et al.
Lowering of Pkd1 expression is sufﬁcient to cause polycystic
kidney disease. Hum Mol Genet. 2004;13:3069–3077.
20. Chebib FT, Jung Y, Heyer CM, et al. Effect of genotype on the
severity and volume progression of polycystic liver disease in
autosomal dominant polycystic kidney disease. Nephrol Dial
Transplant. 2016;31:952–960.
21. Kokudo T, Hasegawa K, Uldry E, et al. A new formula for
calculating standard liver volume for living donor liver
transplantation without using body weight. J Hepatol.
2015;63:848–854.
22. Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver
volume in ADPKD: effects of somatostatin analogue octreo-
tide. Clin J Am Soc Nephrol. 2010;5:783–789.65
